Screening for Short Cervix: The Impact of this New Prenatal Test on Your Practice
Nov 25, 2013 |
Hosted by: Matt Birnholz Guest: David Stone Half of preterm birth occur in pregnancies that were thought to be routine. There is finally a risk-assessment strategy for routine pregnancies that can be coupled with an evidence-based intervention. Universal cervical length screening enables vaginal progesterone treatment for patients with a mid-pregnancy short cervix. New professional society guidelines are driving this significant change in practice. Dr. David Stone, an obstetrician from the Detroit area, has already made this change and is now screening all of his pregnant patients for prematurely short cervix. Dr. Stone first considered using transvaginal ultrasound to screen, since he alrea...
The CerviLenz® Solution: Putting Cervical Length Screening into Practice
Nov 18, 2013 |
Hosted by: Matt Birnholz Guest: Michael G. Ross Cervical length screening for low risk pregnancies identifies patients with a short cervix for vaginal progesterone treatment to prevent preterm birth. With new society practice guidelines, measurement of the cervix as a routine prenatal screening test is underway. Dr. Michael Ross, a Maternal-Fetal Medicine specialist and Medical Director of Cervilenz Inc., discusses how to implement screening for short cervix with the CerviLenz device. CerviLenz is a disposable device that measures cervical length objectively with a quick procedure during a prenatal visit, and can help select patients for whom a transvaginal ultrasound is indicated. Key Refer...
Changes in Prenatal Care: Universal Screening for Short Cervix and Vaginal Progesterone Intervention
Nov 11, 2013 |
Hosted by: Lee Freedman Guest: Jason K. Baxter New obstetrics practice guidelines address universal cervical length screening as a new prenatal test to assess preterm birth risk for all singleton pregnancies. With Level 1 evidence on the efficacy of vaginal progesterone for mid-pregnancy short cervix, there is now an urgent need to identify patients for treatment to prevent preterm birth. Dr. Jason Baxter, a Maternal-Fetal Medicine specialist at Thomas Jefferson University and one of the investigators for the NIH vaginal progesterone study, reviews the evidence and discusses how to implement the new practice guidelines. Key References Hassan SS, Romero R, Vidyadhari D, et al. Vaginal progest...